Navigation Links
AGI Dermatics Clinical Data Indicate Bicyclic Monoterpene Diols Suppress MMP1 and Stimulate Collagen Through TNF-a Signaling
Date:2/11/2008

Clinical Data Presented at the 66th Annual Meeting of the American Academy

of Dermatology

FREEPORT, N.Y., Feb. 11 /PRNewswire/ -- AGI Dermatics clinical research indicates that the ability of bicyclic monoterpene diols (BMTds) to reduce collagenese MMP-1 secretion and increase collagen production is dependent on the TNF-a signaling in the fibroblasts. The data was presented at the Poster Session at the 66th Annual Meeting of the American Academy of Dermatology in San Antonio.

"Our prior research showed that BMTds increase collagen gene expression and protein production while decreasing MMP-1 secretion," said Daniel Yarosh, PhD, President, AGI Dermatics. "This study gives us insight into the cellular communication that allows BMTds to work so effectively and efficiently in treating photodamaged skin."

BMTds, a class of compounds known to increase nitric oxide levels, were recently reported to play a major role in collagen synthesis. AGI scientists questioned whether the transmission of BMTd factors were influenced by the role of Interleukin-6 (IL-6) and TNF-A in regulating collagen 1 and MMP-1 secretions.

In earlier studies of BMTds, AGI scientists observed a linear increase in BMTd concentrations and secretion of interleukin-6 (IL-6), a multi-functional cytokine that mediates a wide variety of functions in cells, promotes cell proliferation and regulates gene expression. By blocking the IL-6 signaling with a neutralizing IL-6 antibody, studies showed a concomitant increase in MMP-1 and a reduction in collagen 1. The effect of the neutralizing antibody, however, was gradually overcome by increasing BMTd concentrations, indicating that IL-6 is not involved in the transmission of the BMTd effect. Results indicated a linear decrease in MMP-1 secretion and an increase in collagen production, two key components in treatment of photoaged skin.

Similarly, blocking TNF-a signaling in the fibroblasts with a TNF-a neutralizing antibody also increases MMP-1 and decreases collagen secretion. However, blocking TNF-a signaling also blocks the BMTd effect.

AGI Dermatics is the developer of Remergent, a doctor-dispensed skincare line based on the science of DNA repair. Pinoxide, an exclusive and patented blend of bicyclic monoterpene diols, is formulated in Remergent Microcirculation Therapy.

About AGI Dermatics

AGI Dermatics is the bio-pharmaceutical laboratory that has led research of DNA repair of the skin for more than 20 years. Founded by Daniel B. Yarosh, PhD, AGI Dermatics specializes in skin photobiology, dedicating research and development to DNA repair, solar impact on the immune system, and cell- signaling in skin. The company's application of groundbreaking active ingredients and meticulously engineered liposome delivery systems is validated in controlled clinical studies and published in dozens of peer-reviewed scientific and medical journals. http://www.agiderm.com


'/>"/>
SOURCE AGI Dermatics
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
3. EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound
4. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
5. Romark Initiates Clinical Trial of Alinia(R) for Chronic Hepatitis C in the United States
6. The Multiple Myeloma Research Consortium (MMRC) and Proteolix Initiate Phase 2 Clinical Trial Investigating Carfilzomib for the Treatment of Multiple Myeloma
7. Millennium Initiates Clinical Trial to EVOLVE the Treatment of Patients with Newly Diagnosed Multiple Myeloma
8. Potential Safety Issue Identified in Ongoing Phase 2 Clinical Study of HCV-796
9. Clinical Trial Effectiveness: How Pharmas & Biotechs Save Cost with Savvy Investigator Management
10. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
11. Phosphagenics Announces Positive Phase 1b Transdermal Insulin Clinical Trial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/19/2016)... , May 19, 2016 ... World Congestive Heart Failure (CHF) Treatment Devices Market - ... CHF treatment devices market would reach $14.8 billion by ... 2022. Implantable cardioverter-defibrillator (ICDs) segment is expected to dominate ... period. North America is projected ...
(Date:5/19/2016)... 19, 2016 Research ... "Global In-Vitro Diagnostics (IVD) Market Size, Market ... Key Players, Competitive Strategies and Forecasts, 2012 ...      (Logo: http://photos.prnewswire.com/prnh/20160330/349511LOGO ... research report forecasts on In-Vitro Diagnostics (IVD) ...
(Date:5/19/2016)...  IBM,s (NYSE:   IBM )  World Community Grid ... drug candidates to cure Zika, a fast spreading virus ... public health emergency. IBM and a global ... or Android device to join the #OpenZika project. Volunteers ... help; they simply  run an app   on ...
Breaking Medicine Technology:
(Date:5/23/2016)... CA (PRWEB) , ... May 23, 2016 , ... Researchers ... is so routine. A fresh look at this technique may yield big benefits. ... reproducibility of experiments in a cell culture laboratory—and lessen the risk of ...
(Date:5/23/2016)... New York, NY (PRWEB) , ... May 23, 2016 , ... ... revolutionary, sport-injury preventative testing program for athletes. This is the first time this type ... South California, is being made available to the public in New York. , With ...
(Date:5/23/2016)... ... 23, 2016 , ... ComplianceOnline, the leading governance, risk and compliance advisory network ... September 15 and 16, 2016 in San Diego, CA. The two day summit ... be one of the largest gatherings of medical device companies, suppliers, professionals and experts ...
(Date:5/23/2016)... ... May 23, 2016 , ... ... today that nominations will be accepted May 23, 2016 through August 5, ... include the Information Security Executive® of the Year, which recognizes executives who ...
(Date:5/23/2016)... ... 23, 2016 , ... Hadley Institute for the Blind and ... blind or visually impaired, announces the election of Julie S. Tye as its ... Board of Trustees retained Morris & Berger, a firm specializing in non-profit executive ...
Breaking Medicine News(10 mins):